Indication:Chronic lymphocytic leukaemia, multiple myeloma
Drug safety update: Increased risk of non-melanoma skin cancer and PML.
It is advised that skin examinations should be periodically performed in patients on bendamustine-containing regimens and PML considered in the differential diagnosis for patients on bendamustine with new or worsening neurological, cognitive, or behavioural signs or symptoms.
MHRA March ’21
Drug safety alert:
Fatal toxicities mainly (opportunistic) infections, but some fatal cardiac, neurological, and respiratory toxicities were also reported.
Drug Safety Update
Increased mortality observed in recent clinical studies in off-label use; monitor for opportunistic infections, hepatitis B reactivation
Bendamustine is recommended as an option for
the first-line treatment of chronic lymphocytic
leukaemia (Binet stage B or C) in patients for
whom fludarabine combination chemotherapy is
NICE Guidance Feb 2011